OPTP

Clarus Medical LLC, based in Minneapolis, MN, specializes in manufacturing high-quality medical devices designed to enhance patient outcomes through precise, minimally invasive procedures. With over 30 years of experience, the company is dedicated to saving lives, minimizing patient trauma, and reducing medical costs through innovative technology. The company offers a range of products including neuroendoscopes and airway intubation scopes, all produced in an ISO 13485 certified cleanroom facility. Clarus Medical also partners with leading medical companies as an OEM manufacturer, catering to specific manufacturing needs in the medical industry. Generated from the website

ABOUT CVRx Company Overview CVRx is a private company located in Minneapolis, Minnesota. The company has developed proprietary active implantable technology for the treatment of high blood pressure, also referred to as hypertension, and heart failure. The CVRx senior management and technical team have many years of experience commercializing implantable medical devices. The company is well financed and supported by an outstanding board of directors. They have established a world-class scientific advisory board, which includes thought leading physicians and scientists in the field of hypertension and heart failure. Hypertension affects over 73 million people in the United States and is estimated to cause 1 in every 8 deaths worldwide1 It is a major risk factor for cardiovascular disease, morbidity and mortality. It is a costly disease and yearly costs to treat hypertension in the United States are estimated to be $69.4 billion1 Twenty-five percent of people with hypertension cannot adequately control their hypertension with medications and lifestyle modifications 2, 3 It is a disease that needs new treatment solutions. Heart failure affects over 5 million people in the United States and is associated with a high risk of dying, with a five-year mortality rate of 74%.4, 5 It has a severe impact on quality of life with symptoms including: general fatigue and weakness; shortness of breath and swelling in the legs and ankles. It is also a costly disease, with an estimated direct and indirect costs of $37.2 billion annually in the United States.6 There are no proven treatments available today that improve the function of the heart in individuals with heart failure caused by heart filling problems, also called diastolic heart failure. Diastolic heart failure accounts for up to 50% of heart failure cases.7

Biomedical Models is the premier provider and distributor of the highest quality anatomical, zoological and botanical models from Somso and Erler-Zimmer.